Astra and Merck win speedy review for Lynparza in breast cancer

LONDON, Oct 18 (Reuters) - U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.